Trial Profile
Double-blind, parallel group, placebo-controlled trial of the efficacy and tolerability of memantine (20 mg) in frontotemporal dementia (FTD) patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2013
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Dementia
- Focus Therapeutic Use
- 22 May 2009 Status changed from recruiting to completed.
- 02 May 2009 Primary endpoint results presented at the 61st Annual Meeting of the American Academy of Neurology
- 02 May 2009 Status change from recruiting to completed